Workflow
上海畅联国际物流股份有限公司2025年半年度报告摘要

Core Viewpoint - Shanghai Changlian International Logistics Co., Ltd. plans to establish a joint venture, Shanghai Changlian Baifu Pharmaceutical Co., Ltd., with Shanghai Waigaoqiao Biomedical Industry Development Co., Ltd. The registered capital of the new company will be RMB 50 million, with Changlian contributing RMB 30 million for a 60% stake, while the biomedical company will contribute RMB 20 million for a 40% stake. This project is not expected to have a significant short-term impact on the company's revenue, profit, or cash flow [3][4][5]. Company Overview - The new company, Shanghai Changlian Baifu Pharmaceutical Co., Ltd., will focus on supply chain management services in the pharmaceutical sector, leveraging Changlian's existing advantages in the medical device sector [5][6]. - The establishment of the new company aligns with the company's strategic goal of expanding into the pharmaceutical sector, enhancing its overall competitiveness [11]. Investment and Transaction Details - The joint investment constitutes a related party transaction, with the investment amount of RMB 30 million representing 1.62% of the company's net assets as of 2024 [6][9]. - The transaction has been approved by the company's independent directors, audit committee, board of directors, and supervisory board, and does not require shareholder approval [4][15][30]. Business Synergy and Market Context - The new company aims to create a standardized logistics warehouse for pharmaceuticals, supporting the development of the biomedical industry in the Shanghai Free Trade Zone [5][10]. - The establishment of the new company is expected to enhance the regional investment ecosystem and foster the development of pharmaceutical research and manufacturing projects [5][9]. Governance Structure - The new company will have a governance structure consisting of a shareholders' meeting, a board of directors, and a general manager, with the board comprising five members [11][12].